Evotec SE
DEEUREvotec SE (XETRA:EVT) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 3. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par uzņēmumu
- Tīmekļvietne
- evotec.com
- Investoru attiecības
- evotec.com/ir-news/investor-relations
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā mītne
- HAMBURG, Germany
- Izpilddirektors
- Dr. Christian Wojczewski Ph.D.
- Darbinieki
- 4 461
- Biržā kopš
- 12.11.1999 (XETRA:EVT)
- Apgrozībā esošās akcijas
- 177.69 milj.
- Brīvā apgrozība
- 135.49 milj.
- Tirgus kapitalizācija
- 521.36 milj. EUR
- Iekšējās personas
- 9.97%
- Institucionālie investori
- 60.05%
- Nozare (SIC)
- Pharmaceutical Preparations
Apraksts
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Dividendes
Dividenžu izmaksas netika atrastas (pārbaudīts 09.10.2026). Uzņēmums, visticamāk, nemaksā dividendes.
Ziņas šonedēļ
Pēdējās nedēļas laikā nav ziņu. Jaunākās ziņas: 29.09.2026.
Lielākie akcionāri
| Turētājs | Daļa | Akcijas | Pārskata datums |
|---|---|---|---|
| First TRT Exch-Trd Fd.-F… | 1.46% | 2.6 milj. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 2.32 milj. | 2026-07-31 |
| Brown Capital Mgmt Mutua… | 1.12% | 2 milj. | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 1.55 milj. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.62% | 1.1 milj. | 2026-08-31 |
| VANGUARD Intl Eqy. INDEX… | 0.37% | 660 978 | 2026-07-31 |
| DCF Advisers, LLC | 0.33% | 1.08 milj. | 2026-06-30 |
| JNL Series Trust-JNL Mul… | 0.3% | 530 535 | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.27% | 477 830 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.26% | 469 700 | 2026-08-31 |
| DFA INVESTMENT DIMENSION… | 0.23% | 414 281 | 2026-07-31 |
| WCM Investment Managemen… | 0.2% | 671 884 | 2026-06-30 |
| ABC Arbitrage SA | 0.11% | 371 936 | 2026-06-30 |
| Optiver Holding B.v. | 0.1% | 322 153 | 2026-06-30 |
| Morgan Stanley | 0.06% | 205 763 | 2026-06-30 |
| LPL Financial LLC | 0.05% | 166 045 | 2026-06-30 |
| Envestnet Asset Manageme… | 0.04% | 139 596 | 2026-06-30 |
| Old Mission Capital, LLC | 0.01% | 38 032 | 2026-06-30 |
| Pathstone Holdings, LLC | 0.01% | 35 779 | 2026-06-30 |
| Fore Capital, LLC | 0.01% | 31 355 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 11 272 | 2026-07-31 |